Publication:
Safety and efficacy of [177Lu]Lu-SibuDAB in patients with progressive metastatic castration-resistant prostate cancer

Thumbnail Image

Files

160.pdf (1.48 MB)

Date

2025-11

Document type

journal article

Collections

Investigación
Total downloads0
Total views0
Bibliographic managers

Authors

Fernández, René, Soza-Ried, Cristian, Kramer, Vasko, Krieger, Korbinian, Müller, Cristina, Qin, Yun, Fliegert, Frank, Ritt, Philipp, Zhernosekov, Konstantin, Amaral, Horacio, Estay, Roberto, Nicolai, Heinz

Publisher

Springer

URI

https://repositorio.udla.cl/handle/udla/2171

DOI

https://doi.org/10.1007/s00259-025-07634-z

Keywords

Efficacy, MCRPC, Prostate cancer, Radiopharmaceutical therapy, Safety, [<sup>177</sup>Lu]Lu-SibuDAB, [Lu-177]Lu-SibuDAB

Citation

Fernández, René; Soza-Ried, Cristian; Kramer, Vasko; Krieger, Korbinian; Müller, Cristina; Qin, Yun; Fliegert, Frank; Ritt, Philipp; Zhernosekov, Konstantin; Amaral, Horacio; Estay, Roberto; Nicolai, Heinz (2026). Safety and efficacy of [177Lu]Lu-SibuDAB in patients with progressive metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 53(4), 2282-2294. https://doi.org/10.1007/s00259-025-07634-z

Abstract

Purpose: Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy (RPT) is a safe and well-tolerated treatment option for metastatic, castration-resistant prostate cancer (mCRPC)...

Research Projects

Organizational Units

Journal Issue

Endorsement

Review

Supplemented By

Referenced By

Usage statistics
01345
Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26